2017


To access this material please log in or register

Register Authorize
2017/№1

What is new in the modern classification of heart failure? Heart failure with mid-range ejection fraction

Ageev F. T., Ovchinnikov A. G., Dreeva Z. V.
Federal State Budgetary Institution, "Russian Cardiology Science and Production Center" of the Ministry of Health of the Russian Federation, 3rd Cherepkovskaya 15a, Moscow 121552

Keywords: heart failure, ejection fraction, classification

DOI: 10.18087/rhfj.2017.1.2337

The article focuses on a new classification of HF patients presented in the 2016 European Guidelines for the diagnosis and treatment of HF based on different levels of LV EF – HF with reduced LV EF (HFrEF), HF with preserved EF (HFpEF), and HF with mid-range EF (HFmrEF)
  1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37 (27):2129–200. DOI:10.1093/eurheartj/ehw128.
  2. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2014;370 (15):1383–92. DOI:10.1056/NEJMoa1313731.
  3. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359 (23):2456–67. DOI:10.1056/NEJMoa0805450.
  4. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV et al. Effects of candesartan in patients with chro­nic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362 (9386):777–81. DOI:10.1016/S0140–6736 (03) 14285–7.
  5. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78 (8):902–7.
  6. Flather MD. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal. 2004;26 (3):215–25. DOI:10.1093/eurheartj/ehi115.
  7. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B et al. Effects of candesartan in patients with chro­nic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362 (9386):772–6. DOI:10.1016/S0140–6736 (03) 14284–5.
  8. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371 (11):993–1004. DOI:10.1056/NEJMoa1409077.
  9. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CSP, Maggioni AP et al. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA. 2015;314 (21):2251–62. DOI:10.1001/jama.2015.15734.
  10. Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014;16 (9):1026–38. DOI:10.1002/ejhf.135.
  11. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355 (3):251–9. DOI:10.1056/NEJMoa052256.
  12. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353 (9146):9–13.
  13. Solomon SD, Anavekar N, Skali H, McMurray JJV, Swedberg K, Yusuf S et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation. 2005;112 (24):3738–44. DOI:10.1161/CIRCULATIONAHA. 105.561423.
  14. Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123 (18):2006–2013; discussion 2014. DOI:10.1161/CIRCULATIONAHA.110.954388.
  15. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Сравнительная характеристика больных с ХСН в зависимости от величины фракции выброса по результатам Российского многоцентрового исследования ЭПОХА–О–ХСН: снова о проблеме ХСН с сохраненной систолической функцией левого желудочка. Журнал Сердечная Недостаточность. 2006;7 (4):164–71 [Mareev V. Yu., Danielyan M. O., Belenkov Yu. N. Sravnitel`naya xarakteristika bol`ny`x s XSN v zavisimosti ot velichiny` frakczii vy`brosa po rezul`tatam Rossijskogo mnogoczentrovogo issledovaniya E`POXA–O–XSN: snova o probleme XSN s soxranennoj sistolicheskoj funkcziej levogo zheludochka. Zhurnal Serdechnaya Nedostatochnost`. 2006;7 (4):164–71].
  16. Lam CSP, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail. 2014;16 (10):1049–55. DOI:10.1002/ejhf.159.
  17. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27 (19):2338–45. DOI:10.1093/eurheartj/ehl250.
  18. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37 (5):455–62. DOI:10.1093/eurheartj/ehv464.
  19. Tsao CW, Lyass A, Larson MG, Cheng S, Lam CSP, Aragam JR et al. Prognosis of Adults With Borderline Left Ventricular Ejection Fraction. JACC Heart Fail. 2016;4 (6):502–10. DOI:10.1016/j.jchf.2016.03.003.
Ageev F. T., Ovchinnikov A. G., Dreeva Z. V. What is new in the modern classification of heart failure? Heart failure with mid-range ejection fraction. Russian Heart Failure Journal. 2017;18 (1):67–71

To access this material please log in or register

Register Authorize
Ru En